Alerts
Regulators Start Writing the Rules for AI-Driven Medicines
The joint FDA-EMA principles for AI in drug development show regulators trying to align before AI becomes embedded across discovery, trials, manufacturing and post-market safety.
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
AI Mental Health Support Becomes a Governance Test
Alzheimer’s Drugs Force NICE Back Into the Value Debate
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.